Updating How We Classify MS and Why it Matters
It’s Time for a Change
Why This Matters
What's Next
There is a feeling that we need to work with urgency because the current descriptors aren’t working well for us. But we also need to be cautious because there are a lot of implications for this change.Changing how we describe MS will impact people with MS and their family members, healthcare providers, regulators, drug development companies, insurance companies — the list goes on. Some implications we can anticipate, and others we cannot. That means this change has to be made thoughtfully, considering all of the downstream consequences.There will need to be a lot of preparation, so this isn’t happening tomorrow. We look forward to sharing more as we continue our progress.
Bruce Bebo, PhD, is Executive Vice President, Research at the National MS Society and was previously a research immunologist focusing on the influence of sex hormones on MS. He is a driven and passionate Society volunteer, successful fundraiser and advocate, fueled in part by the fact that his mother had MS.
